Tianshui Zhongxing Bio-Technology unveils stock option incentive plan

Tianshui Zhongxing Bio-Technology has announced its 2025 stock option incentive plan, proposing to grant 14.375 million stock options, representing 3.66% of its total share capital. The initial grant comprises 11.5 million options, with 2.875 million options reserved for future grants. The exercise price for these options is set at 6.87 yuan per share, valid for a maximum of 60 months.

The plan targets 17 individuals, including directors, senior management, and core technical personnel, excluding independent directors and major shareholders. Performance targets for 2025-2027 include achieving at least 2.1 billion yuan in operating revenue or a non-recurring net profit growth of 55% over 2024. The first tranche allows for 40% of options to be exercised, followed by 30% for the second and third tranches, provided individual and company performance metrics are met.

The company's board of directors, including chairman Gao Boshu and general manager Liu Liang, approved the plan on September 25, 2025. This decision will be presented for shareholder approval at the third extraordinary general meeting on October 15, 2025.